Comparison of the effects of carvedilol and nebivolol on diastolic functions of the left ventricle in patients with non-ischemic heart failure by Dogan, Abdullah et al.
Address for correspondence: Abdullah Dogan, MD, Department of Cardiology, Medical Faculty, Suleyman Demirel University, 
Isparta, Gazi Kemal Mah 1309 Sokak, Sarac Sitesi C blok No:9/5 32100, Turkey, fax: +90 246 2371758,  
e-mail: adogan35@hotmail.com
Received: 22.03.2013 Accepted: 15.05.2013
ORIGINAL ARTICLE
Cardiology Journal 
2014, Vol. 21, No. 1, pp. 76–82
DOI: 10.5603/CJ.a2013.0062 
Copyright © 2014 Via Medica
ISSN 1897–5593
76 www.cardiologyjournal.org
Comparison of the effects of carvedilol and  
nebivolol on diastolic functions of the left ventricle 
in patients with non-ischemic heart failure
Abdullah Dogan1, Mustafa Karabacak2, Şenol Tayyar3,  
Dogan Erdogan1, Mehmet Ozaydin1
1Department of Cardiology, Medical Faculty, Suleyman Demirel University, Isparta, Turkey 
2Physician in Cardiology, Medical Faculty, Suleyman Demirel University, Isparta, Turkey 
3Pysician in Cardiology, Agrı State Hospital, Agrı, Turkey.
Abstract
Background: We investigated whether carvediolol or nebiovolol with vasodilator properties 
will produce different effects on diastolic function of the left ventricle (LV) in heart failure (HF) 
with low ejection fraction (EF).
Methods: Sixty-one non-ischemic HF patients with EF £ 40% randomly received carvedilol 
(n = 31, 16 male) or nebivolol (n = 30, 19 male). Clinical and echocardiographic evaluations 
were performed at baseline, 3 and 6 months after therapy. Mitral inflow velocities (E and  
A waves), deceleration time of E wave (DT), isovolumetric relaxation time (IVRT), mitral annu - 
lar velocities (Ea and Aa waves) were evaluated. Mitral E/A and E/Ea ratios were calculated.
Results: In carvediolol and nebivolol groups, mitral E/A ratio (from 1.08 ± 0.31 to 0.87 ±  
± 0.30 vs. from 0.98 ± 0.20 to 0.80 ± 0.20, p = 0.30) and IVRT (from 108 ± 13 to 94 ±  
± 10 ms vs. from 107 ± 22 to 92 ± 10 ms, p = 0.25) similarly decreased while DT prolonged 
(from 184 ± 40 to 218 ± 42 ms vs. from 193 ± 37 to 222 ± 36 ms, p = 0.71). Also, E/Ea 
ratio significantly decreased in each group (p = 0.01), but it was lower in nebivolol group than 
carvedilol group at 6 months (10.2 ± 2 vs. 11.8 ± 2, p = 0.01). Carvediolol and nebivolol 
reduced similarly N-terminal pro-B type natriuretic peptide level (from 666 to 137 vs. 661 to 
123 pg/dL, p = 0.41, respectively) and improved functional capacity (p > 0.05).
Conclusions: At 6 month follow-up, carvedilol and nebivolol appear to similarly improve LV 
diastolic functions in non-ischemic HF patients. (Cardiol J 2014; 21, 1: 76–82)
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Introduction
Despite therapeutic advances, heart failure 
(HF) is a disabling disease with poor prognosis [1]. 
Beta-blockers are cornerstone agents in HF the-
rapy because they prevent the deleterious effects 
of activation of sympathetic nervous system [1, 2]. 
Diastolic abnormalities of the left ventricle (LV) are 
important determinants for exercise intolerance in 
HF patients [3, 4].
Carvedilol and nebiovolol are new-generation 
agents with favourable vasodilator and/or antioxi-
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dant properties, and they are used for chronic HF 
treatment [1, 5, 6]. They can reverse cardiac remo-
deling resulting from sympathetic overactivation 
in HF patients [7–11]. Moreover, they improve 
symptoms and survival in HF patients [9, 11–14]. 
However, there is uncertainity whether their fova-
rable effects will similarly produce clinical benefit, 
and carvediolol may be preferred to nebivolol in 
HF patients [15].
On the other hand, 3 previous studies compared 
the effects of these 2 agents on LV functions in HF 
patients [9–11]. They have provided divergent re-
sults about LV diastolic functions at 6- to 24-month 
follow-up. In addition, transmitral to mitral annular 
early diastolic velocity ratio (E/Ea), a sensitive 
marker for high diastolic filling pressure [16] has not 
been evaluated in those studies. Thus, we aimed to 
compare the effects of carvedilol and nebivolol on 
LV diastolic functions and N-terminal pro-B-type na-
triuretic peptide (NT-proBNP) level in non-ischemic 
HF patients with reduced systolic function.
Methods
Patients and dose titration of study drugs
This study included 68 consecutive patients 
with moderate or severe symtomatic HF (New 
York Heart Association [NYHA] class II to III) 
who had angiographically normal coronary arte-
ries. However, 7 patients were excluded from the 
study because of recent atrial fibrillation (n = 2), 
beta-blocker intolerance (n = 2), NYHA class IV 
HF at the time of randomization (n = 1) and re-
fusal to repeat examinations (n = 2). Finally, the 
remaining 61 patients were randomly assigned to 
receive carvedilol (n = 31) or nebivolol (n = 30) in 
a single-blind and open-label fashion. They had LV 
ejection fraction (EF) £ 40% in previous 3 months. 
The patients who had the following features were 
not considered for inclusion into this study at the 
beginning. These features were HF with significant 
coronary stenosis, history of myocardial infarction, 
moderate or severe valvular heart disease, rest 
heart rate < 60 bpm, systolic blood pressure 
(SBP) < 100 mm Hg, history of asthma or use of 
bronchodilators, hypo- or hyperthyroidism, hepatic 
or renal failure (serum creatinin > 2.0 mg/dL), 
rhythm disturbances including second or third 
degree heart block, sick sinus syndrome, atrial 
fibrillation, and complete bundle branch block.
In patients who were on beta-blocker therapy 
before the study, beta-blocker therapy was stop-
ped at least 1 week for drug elimination. There-
after, carvedilol was started at 3.125 mg twice da-
ily and then up-titrated to 6.25, 12.5 and 25 mg 
(target dose) twice a day at 3 to 5-day intervals if 
the previous dose was tolerated. Similarly, ne-
bivolol was given at 1.25 mg once a day and then 
up-titrated to 2.5, 5 and 10 mg (target dose) once 
a day if the previous dose was tolerated. When the 
up-titration dose was not tolerated, the previous to-
lerable dose was considered maximum tolerable dose 
for each agent. The patient’s tolerance was evaluated 
according to the following criteria; resting heart 
rate > 55 bpm, SBP ≥ 100 mm Hg, no drop in SBP 
< 30 mm Hg on standing position, no new symptoms 
of dizziness, or dyspnea. After the target or maximum 
tolerable dose, patients were evaluated in an out-
-patient clinic at 1st, 3rd and 6th month. Complete blood 
count, biochemical analysis and echocardiographic 
measurements were made in patients at baseline, 
3 and 6 months after target dose. Heart rate, BP 
and body weight were recored at each visit. Also, 
functional status of patients was assessed according 
to NYHA. Other medications were prescribed accor-
ding to current chronic HF guideline [1]. All patients 
received angiotensin-converting enzyme inhibitor 
(ACEI, lisinopiril) and diuretics in appropriate doses. 
Candesartan, angiotensin receptor blockers (ARB) 
were given when ACEI intolerance occured.
Blood sampling and assays
Blood samples were drawn for routine hema-
tological and biochemical analyses. Biochemical 
analyses were preformed with “Olympus AU-640”. 
For NT-proBNP assays, a 5-mL blood sample was 
collected into a plastic tube containing potassium 
EDTA. Plasma level of NT-proBNP was measured 
by using an electrochemiluminiscence immuno-
assay with Elecsys 2010 analyser (Roche Diagno-
stics, Mannheim, Germany).
Echocardiography
Echocardiographic examinations were perfor-
med by the same investigator (MK) who blinded to 
the patients’ data at baseline, 3 and 6 months. Measu-
rements were acquired at the end of expiration during 
normal breathing in the left lateral decubitus position. 
Two-dimensional, M-mode, and Doppler echocar-
diographic measurements were obtained according 
to the recommendations of the American Society of 
Echocardiography with System 5 Echocardiography 
Machine (GE Vingmed Ultrasound) with a 2.5 MHz 
transducer [17]. The mean of 3 cardiac cycles with 
ECG record was evaluated for measurements. The 
left atrial size, LV diameters and wall thickness were 
measured by using M-mode echocardiography. LVEF 
was calculated by Simpson’s method.
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The transmitral flow was recorded from the apical 
4-chamber view with the pulsed Doppler. Sample vo-
lume was placed at the tips of the mitral leaflet during 
diastole. The following variables were measured from 
transmitral flow: peak early diastolic (E) wave velocity, 
late diastolic (A) wave velocity, E/A ratio, and E wave 
deceleration time (DT). Isovolumetric relaxation time 
(IVRT) was calculated in apical 5-chamber view [17].
Pulsed Doppler tissue images were obtained 
from the apical 4-chamber view with minimum 
frame rates of 100/s. At least 3 consecutive traces 
of septal and lateral segments of mitral annulus 
were recorded. Their peak early (Ea-wave) and late 
diastolic velocity (Aa-wave) were measured and the 
Ea/Aa ratio was estimated. The average of septal and 
lateral annular velocities was calculated and consi-
dered the final mitral annular velocity. Therafter, 
E/Ea ratio was calculated. With some measure-
ments, intraobserver variabilities were 5.2%, 7.2% 
and 3.8% for EF, IVRT and E/Ea, respectively.
The study was approved by the institutional 
ethics committee and informed consent was obtai-
ned from each patient.
Statistical analyses
All analyses were performed with commercially 
available statistical program (SPSS Version 13.0, 
SPSS Inc., Chicago, IL). Continous variables were 
presented as mean ± standard deviation and categoric 
ones as percentage (%). The two study groups were 
compared using Student-t test or Mann-Whitney U 
and c2 or Fisher exact test as appropriate. In each 
group, follow-up comparisons (baseline and 6 months) 
were performed by using Paired t-test and Wilcoxon 
ranked tests as appropriate. A 2-tailed p value of 
< 0.05 was considered statistically significant.
Results
Baseline demographic and clinical features 
except the use of aspirine were comparable in 
carvedilol and nebiovolol groups (Table 1). Laborato-
ry tests and initial echocardiographic measurements 
were also similar in the two groups (Tables 1, 2). 
Target dose of study drugs was reached in 42% and 
47% of patients in carvedilol and nebivolol groups, 
respectively (p = 0.85).
Table 1. Demographic, clinical and laboratory characteristics of carvediolol and nebivolol groups.
Carvedilol group (n = 31) Nebivolol group (n = 30) P
Mean age [year] 61 ± 11 60 ± 14 0.73
Male/female 16/15 19/11 0.36
Body weight [kg] 78 ± 18 75 ± 12 0.48
NYHA class II/III 52%/48% 60%/40% 0.61
Current smoker 8 (26%) 11 (37%) 0.42
Hypertension 15 (45%) 15 (48%) 0.90
Diabetes mellitus 5 (16%) 5 (17%) 0.99
Hyperlipidemia 7 (22%) 10 (33%) 0.40
Obesity (BMI ≥ 30 kg/m2) 11 (35%) 8 (26%) 0.46
Systolic BP [mm Hg] 143 ± 17 141 ± 13 0.57
Diastolic BP [mm Hg] 91 ± 15 90 ± 10 0.60
Heart rate [bpm] 81 ± 9 82 ± 9 0.72
Medications:
ACEI/ARB 29 (93%)/2 (7%) 28 (93%)/2 (7%) 0.96
Spirinolacton 9 (29%) 5 (17%) 0.25
Other diuretics 31 (100%) 30 (100%) 0.99
Statins 4 (13%) 2 (7%) 0.67
Digoxin 2 (6%) 2 (7%) 0.97
Aspirin 20 (64%) 11 (36%) 0.03
Creatinine [mg/dL] 0.97 ± 0.2 1.0 ± 0.3 0.27
Sodium [mEq/L] 140 ± 3.3 141 ± 3.6 0.27
Potassium [mEq/L] 4.4 ± 0.4 4.4 ± 0.4 0.84
Hematocrit [%] 42 ± 4.7 42 ± 4.8 0.72
NT-proBNP [pg/mL] 666 (442–1350) 661 (455–1013) 0.61
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin-1 receptor blockers; BMI — body mass index; BP — blood pressure; 
NYHA — New York Heart Association; NT-proBNP — N-terminal pro-B-type natriuretic peptide
www.cardiologyjournal.org 79
Abdullah Dogan et al., Carvedilol or nebivolol in diastolic dysfunction
Table 3 shows temporal changes in clinical 
and echocardiographical variables of both groups at 
3 and 6 months. Heart rate, BP and body weight sig-
nificantly decreased in each group (each p = 0.01), 
but these reductions were similar in both groups. 
Similarly, functional class significantly improved in 
each group (p = 0.01), but was comparable in both 
groups (p = 0.54, Table 3, Fig. 1). In addition, con-
comitant medications did not differ in both groups. 
Four patients received candesartan due to ACEI 
intolerance (2 patients in each group).
The LV diameters and EF significantly impro-
ved in each group at 6 months (Table 3). Compared 
with the carvedilol group, EF was slightly higher in 
the nebivolol group due to bigger reduction of LV 
systolic diameter at 3 months, but it was similar 
in the two groups at 6 months.
In each group, mitral E velocity and E/A ra-
tio significantly decreased (each p = 0.01) while 
A velocity remained unchanged (Table 3). However, 
these reductions were similar in both groups. Simi-
larly, DT and IVRT significantly improved in each 
therapy group (each p < 0.05). However, these 
improvements were also comparable in the two 
groups at 3 and 6 months (Table 3). Mitral Ea/Aa 
ratio did not differ in the two groups, although 
Aa velocity was lower in the carvedilol group than in 
the nebivolol group (p = 0.04). On the other hand, 
E/Ea ratio significantly decreased in each group 
(p = 0.01), but it was lower in the nebivolol group 
than in the carvedilol group at 6 months (10.2 ± 2 
vs. 11.8 ± 2, p < 0.01).
During 6 months, median NT-proBNP levels 
were significantly reduced with carvediolol or 
nebivolol therapy (p < 0.001, Table 3). However, 
this reduction was comparable in the two groups 
at 3 and 6 months.
At follow-up, there was no death, hospitaliza-
tion for HF or discontinuation of study drugs for 
adverse effects. Drugs were well tolerated.
Discussion
In the present study, mitral E/A ratio and IVRT 
similarly decreased in nonischemic HF patients 
who were treated with carvediolol or nebivolol at 
6 months while DT similarly prolonged. Also, E/Ea 
ratio significantly decreased in each therapy group.
Clinical data have showed that carvedilol 
and nebivolol have beneficial effects on clinical 
outcomes, such as symptoms, exercise capacity 
and prognosis in HF patients with reduced EF [9, 
11–14]. These useful effects are frequently attri-
buted to the elevated LVEF due to reduction in LV 
volumes [8, 9, 11–14].
On the other hand, diastolic function is impor-
tant for symptoms and prognosis in HF patients. 
Symptoms and functional capacity can be more 
related to diastolic dysfunction more than systolic 
dysfunction in HF patients [3, 4]. Beta-blockers 
can frequently improve LV diastolic function in 
association with an increase in EF of HF patients 
[18, 19]. However, they can recover diastolic dys-
function even without a concomitant EF elevation 
Table 2. Baseline echocardiographic parameters of carvediolol and nebivolol groups.
Carvedilol (n = 31) Nebivolol (n = 30) P
LV diastolic diameter [mm] 58 ± 7 57 ± 6 0.65
LV systolic diameter [mm] 46 ± 7 44 ± 6 0.22
Septal thickness [mm] 11 ± 1.2 11 ± 1.5 0.48
Posterior wall thickness [mm] 11 ± 1.1 10 ± 1.1 0.08
LV ejection fraction [%] 33 ± 4.2 34 ± 4.9 0.22
LA diameter [mm] 43.4 ± 4.2 41.5 ± 4.1 0.68
Mitral E velocity [cm/s] 90 ± 13 86 ± 18 0.30
Mitral A velocity [cm/s] 84 ± 24 90 ± 18 0.31
Mitral E/A ratio 1.08 ± 0.31 0.98 ± 0.26 0.19
Mitral DT [ms] 184 ± 40 193 ± 37 0.33
IVRT [ms] 108 ± 13 107 ± 22 0.83
Mitral Ea [cm/s] 6.7 ± 1 6.8 ± 2 0.87
Mitral Aa [cm/s] 8.4 ± 2 8.8 ± 2 0.33
Ea/Aa ratio 0.78 ± 0.1 0.78 ± 0.3 0.98
E/Ea ratio 14.0 ± 2.5 13.1 ± 2.9 0.24
Aa — mitral annular late diastolic velocity; DT — deceleration time of mitral E wave; Ea — mitral annular early diastolic velocity;  
IVRT — isovolumetric relaxation time; LA — left atrium; LV — left ventricle
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Figure 1. Functional capacity in carvedilol and nebi-
volol groups and its temporal changes with therapy. 
Although it significantly improved in each group, there 
was no significant difference between the two groups 
at 3 and 6 months (p > 0.05); FC — functional capacity.
Table 3. Temporal changes in clinical and echocardiographic variables at 3 and 6 months.
Carvedilol (n = 31) Nebivolol (n = 30) P
3 months 6 months 3 months 6 months P1 P2
NYHA class I–II 81% 96%* 86% 93%* 0.45 0.54
HR [bpm] 75 ± 8 67 ± 7* 74 ± 9 66 ± 6* 0.78 0.52
SBP [mm Hg] 137 ± 14 122 ± 14* 132 ± 12 118 ± 15* 0.10 0.27
DBP [mm Hg] 85 ± 10 75 ± 12* 82 ± 8 71 ± 9* 0.14 0.10
Weight [kg] 76 ± 17 76 ± 18* 73 ± 11 73 ± 12* 0.43 0.44
LVEDD [mm] 58 ± 7 57 ± 7* 56 ± 6 55 ± 5* 0.16 0.16
LVESD [mm] 46 ± 7 44 ± 7* 42 ± 7 41 ± 7* 0.07 0.07
LVEF [%] 33 ± 5 36 ± 5* 36 ± 5 37 ± 5* 0.09 0.30
LAD [mm] 43.4 ± 4.4 42.4 ± 4.7 41.0 ± 3.9 40.6 ± 3.8 0.26 0.19
E [cm/s] 82 ± 10 74 ± 1* 77 ± 20 69 ± 20* 0.17 0.31
A [cm/s] 89 ± 20 85 ± 20 89 ± 10 86 ± 20 0.87 0.81
E/A 0.92 ± 0.2 0.87 ± 0.3* 0.86 ± 0.2 0.80 ± 0.2* 0.37 0.30
DT [ms] 196 ± 39 218 ± 42* 199 ± 34 222 ± 36* 0.77 0.71
IVRT [ms] 101 ± 12 94 ± 10* 98 ± 15 92 ± 10* 0.43 0.25
Ea [cm/s] 6.6 ± 1.4 6.4 ± 1.6 6.9 ± 1.5 6.8 ± 1 0.43 0.35
Aa [cm/s] 8.1 ± 1.7 7.8 ± 1.5* 8.6 ± 1.6 8.6 ± 1.5 0.28 0.04
Ea/Aa 0.83 ± 0.2 0.79 ± 0.2 0.78 ± 0.2 0.79 ± 0.2 0.39 0.99
E/Ea 12.6 ± 2 11.8 ± 2* 11.5 ± 3 10.2 ± 2* 0.15 0.01
NT-proBNP [pg/mL] 445 (226–845) 137 (113–216)* 395 (299–661) 123 (105–186)* 0.87 0.41
*p < 0.05 vs. baseline in each group; P1 — comparisons of two groups at 3 months; P2 — comparisons of two groups at 6 months; A — mitral 
late diastolic velocity; DBP — diastolic blood pressure; HR — heart rate; LAD — left atrial diameter; LVEDD — left ventricular end-diastolic 
diameter; LVESD — left ventricular end-systolic diameter; LVEF — left ventricular ejection fraction; SBP — systolic blood pressure; other 
abbreviations are as shown in Table 1 and 2. 
in such patients [20]. There are several expla-
nations for their favorable effects. Beta-blockers 
reduce heart rate and prolong the diastolic period, 
thereby decreasing both oxygen consumption 
of myocardium and increasing oxygen supply to 
myocardium. Consequently, they can improve 
myocardial relaxation or diastolic functions and 
metabolism [15, 21].
Despite a low diagnostic value, mitral E/A 
ratio is commonly used for LV diastolic function 
in practice. Carvedilol [7, 9, 10, 18, 20, 22–24] and 
nebivolol [8–10, 19, 25, 26] have been reported to 
have different effects on mitral E wave velocity and 
E/A ratio in previous studies. In our study, mitral 
E/A ratio was similarly reduced with carvedilol 
or nebivolol therapy due to reduction of mitral 
E wave velocity. This finding is in accordance with 
the results from previous studies [10, 18–20, 22]. 
In contrast, Patrianakos et al. [9] have reported that 
mitral E/A ratio was significantly decreased with 
nebivolol treatment in nonischemic HF patients at 
12-month follow-up, but not with carvedilol therapy.
We observed a significant improvement in DT 
and IVRT variables with carvediolol or nebivolol 
therapy, but there was no difference between the 
two therapy groups. Patrianakos et al. [9] have 
showed that DT was similarly prolonged with 
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both study drugs, with earlier improvement with 
carvedilol. A 12-month nebivolol therapy resulted 
in a trend toward reduction in mitral E/A ratio 
and prolongation in DT in elderly HF patients in 
echocardiographic substudy of SENIORS study [8]. 
These useful effects may be due to vasodilatory 
action of both agents.
In HF patients with low EF, carvedilol therapy 
reduced mitral E velocity, E/A ratio and IVRT while 
it prolonged DT [18, 20, 22], as in our study. In con-
trast, mitral inflow velocities and mitral E/A ratio 
remained unchanged with carvedilol therapy in HF 
patients in previous two studies [9, 10]. Similarly, 
Sugioka et al. [24] have reported that carvedilol 
did not affect mitral E wave and E/A ratio but sig-
nificantly prolonged DT in patients with idiopathic 
dilated cardiomyopathy after 6-month therapy.
E/Ea ratio is a reliable marker for LV diastolic 
function and well correlated with LV filling pres-
sures [16]. Its value of > 15 presents high LV filling 
pressure and has predictive value for cardiac events 
in patients with LV dysfunction [16, 27]. To our 
knowledge, there is no data about the comparative 
effects of carvediolol and nebivolol on E/Ea ratio in 
HF patients. In our study, both agents significantly 
reduced the E/Ea ratio during 6 months. Although 
E/Ea ratio was lower in nebivolol group than in the 
carvedilol group at 6 months, this difference will 
not provide any clinical benefit since both values 
are in range of 8 to 15. In another study, carvedilol 
has decreased E/Ea ratio significantly in patients 
with dilated cardiomyopathy secondary to muscular 
dystrophy [23].
Owing to the improvement in LV hemodynamics, 
beta-blocker therapy with an ACEI or ARB is likely 
to reduce NT-proBNP levels over time, but previous 
results are divergent [10, 28–30]. These results might 
be due to small sample size, variable follow-up time 
and differences between study populations. Both 
carvedilol and nebivolol therapy similarly reduced 
NT-proBNP levels in our study at 3 and 6 months 
but there was no difference in neither therapy group. 
However, Lombardo et al. [10] have reported no 
reduction in NT-proBNP levels in carvediolol and 
nebivolol groups at 6-month follow-up.
In parallel to echocardiographic and neurohor-
monal improvement, we observed that both study 
drugs to a similar extent significantly improved 
functional capacity, heart rate and BP. These fin-
dings are concordant with the results from previous 
studies [7, 9–14, 18–20, 22, 23, 25].
Limitations of the study
There are several limitations to our study. 
Firstly, the small size of our study limits the stati-
stical power since we applied strict non-inclusion 
criteria for the study. Secondly, we evaluated clini-
cally the functional capacity of patients instead of 
exercise test or 6-minute walking distance. Also, 
we did not use the life-quality scoring systems. 
Thirdly, we would measure left atrial volume inste-
ad of its diameter. Finally, our findings reflect the 
situation only in patients with non-ischemic HF. It 
may be possible that carvedilol and nebivolol might 
have different effects on LV diastolic function in 
ischemic HF patients.
Conclusions
Our findings show that carvedilol and nebivolol 
have similar effects on LV diastolic functions and 
NT-proBNP levels in non-ischemic HF patients 
with reduced EF.
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